Novo Nordisk CEO warns tariffs could send the prices of Ozempic and Wegovy higher
Insurance companies generally cover Ozempic and Wegovy when it is prescribed for Type 2 diabetes. However, when the drugs are ...
Notable analyst calls this week: Verizon, Novo Nordisk and Intel stocks among top picks
Get key updates on stock ratings this week, from Intel's leadership-driven upgrade to Apple's tariff challenges.
Down 39%. Is Novo Nordisk Stock a Buy on the Dip?
Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...
Fierce Pharma5d
Novo Nordisk invites people with Type 2 diabetes into their ‘Ozempic Eras’ in star-studded campaign
In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...
Novo Nordisk Launches National "My Ozempic® Era" Campaign Celebrating Stories of Inspirational Ozempic® Patients
Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...
Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain.
The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.
Novo Nordisk stock slides Monday on second-generation GLP-1 data
Novo Nordisk stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP ...